Literature DB >> 29315805

Gender-specific risk factors for low bone mineral density in patients taking antipsychotics for psychosis.

Min Jhon1, Taeyoung Yoo1, Ju-Yeon Lee1,2, Seon-Young Kim1, Jae-Min Kim1, Il-Seon Shin1, Lana Williams3, Michael Berk3,4, Jin-Sang Yoon1, Sung-Wan Kim1,2.   

Abstract

OBJECTIVE: This study examined clinical and gender-specific risk factors for low bone mineral density (BMD) in adult patients with psychotic disorders.
METHODS: The study included 285 community-dwelling patients with psychotic disorders. Dual-energy X-ray absorptiometry was used to measure BMD. Clinical characteristics associated with low BMD were identified with logistic regression analysis in total population and each gender.
RESULTS: Fifty-eight (20.4%) subjects had low BMD. Low BMD was more common in men and in patients with low body mass indices (BMIs), as well as in those with shorter treatment durations, those on Medicaid, and patients using serotonergic antidepressants. Logistic regression analysis revealed that low BMD was negatively associated with BMI and treatment duration and positively with gender (male) and serotonergic antidepressants use in the overall population. In men, low BMD was associated with treatment duration and BMI; in women, low BMD was associated with BMI, prolactin level, vitamin D, and serotonergic antidepressant use.
CONCLUSION: Managing the risk factors associated with low BMD among patients with psychotic disorder should be done gender-specifically. Psychotropic agents should be prescribed mindful of their effects on bone, as use of these medications is a modifiable risk factor for osteoporosis in women with psychotic disorders.
Copyright © 2018 John Wiley & Sons, Ltd.

Entities:  

Keywords:  body mass index; bone mineral density; prolactin; psychosis; schizophrenia; serotonergic antidepressant

Mesh:

Substances:

Year:  2018        PMID: 29315805     DOI: 10.1002/hup.2648

Source DB:  PubMed          Journal:  Hum Psychopharmacol        ISSN: 0885-6222            Impact factor:   1.672


  5 in total

1.  Latent Iron Deficiency as a Marker of Negative Symptoms in Patients with First-Episode Schizophrenia Spectrum Disorder.

Authors:  Sung-Wan Kim; Robert Stewart; Woo-Young Park; Min Jhon; Ju-Yeon Lee; Seon-Young Kim; Jae-Min Kim; Paul Amminger; Young-Chul Chung; Jin-Sang Yoon
Journal:  Nutrients       Date:  2018-11-08       Impact factor: 5.717

2.  Effect of Vitamin D Supplementation on Outcomes in People With Early Psychosis: The DFEND Randomized Clinical Trial.

Authors:  Fiona Gaughran; Dominic Stringer; Gabriella Wojewodka; Sabine Landau; Shubulade Smith; Poonam Gardner-Sood; David Taylor; Harriet Jordan; Eromona Whiskey; Amir Krivoy; Simone Ciufolini; Brendon Stubbs; Cecilia Casetta; Julie Williams; Susan Moore; Lauren Allen; Shanaya Rathod; Andrew Boardman; Rehab Khalifa; Mudasir Firdosi; Philip McGuire; Michael Berk; John McGrath
Journal:  JAMA Netw Open       Date:  2021-12-01

3.  DNA Methylation Profiles of the DRD2 and NR3C1 Genes in Patients with Recent-Onset Psychosis.

Authors:  Yan Hong Piao; Yin Cui; Ling Li; Maryam Karamikheirabad; Sung-Wan Kim; Bong Ju Lee; Jung Jin Kim; Je-Chun Yu; Kyu Young Lee; Seung-Hee Won; Seung-Hwan Lee; Seung-Hyun Kim; Shi Hyun Kang; Euitae Kim; Nam-In Kang; Fatima Zahra Rami; Young-Chul Chung
Journal:  Dis Markers       Date:  2022-08-03       Impact factor: 3.464

4.  Methylome-wide Association Study of Patients with Recent-onset Psychosis.

Authors:  Yan-Hong Piao; Yin Cui; Fatima Zahra Rami; Ling Li; Maryam Karamikheirabad; Shi Hyun Kang; Sung-Wan Kim; Jung Jin Kim; Bong Ju Lee; Young-Chul Chung
Journal:  Clin Psychopharmacol Neurosci       Date:  2022-08-31       Impact factor: 3.731

5.  Altered levels of BMD, PRL, BAP and TRACP-5b in male chronic patients with schizophrenia.

Authors:  Xiangdong Du; Fei Ye; Jin Li; Yaqin Zhao; Wenhuan Xiao; Xiaowei Tang; Xiaobin Zhang
Journal:  Sci Rep       Date:  2020-08-12       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.